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A total of 2,811 clinical isolates of Haemopbilus influenzae were obtained during 1986 from 30 medical
centers and one nationwide private independent laboratory in the United States. Among these, 757 (26.9%)
were type b strains. The overall rate of 3-lactamase-mediated ampicillin resistance was 20.0%. Type b strains
were approximately twice as likely as non-type b strains to produce (-lactamase (31.7 versus 15.6%). The
MICs of 12 antimicrobial agents were determined for all isolates. Ampicillin resistance among strains that
lacked (3-lactamase activity was extremely uncommon (0.1%). Percentages of study isolates susceptible to
cefamandole, cefaclor, cephalothin, and cephalexin were 98.7, 94.5, 87.3, and 43.3%, respectively. For 14
strains (0.5% of the total), chloramphenicol MICs were -8.0 ,ug, and thus the strains were considered
resistant. All of these resistant strains produced chlorainphenicol acetyltransferase. In addition, all 14 strains
were resistant to tetracycline; 11 produced j3-lactamase. The percentage of isolates susceptible to tetracycline
was 97.7%. In contrast, erythromycin and sulfisoxazole were relatively inactive. The combination of
erythromycin-sulfisoxazole (1/64) was more active than erythromycin alone but essentially equivalent in activity
to sulfisoxazole alone. Finally, small numbers of clinical isolates of H. influenzae were resistant to trimetho-
prim-sulfamethoxazole and rifampin.
Antimicrobial resistance among clinical isolates of Hae-
mophilus influenzae has become an increasingly prevalent
problem (G. V. Doern, Antimicrob. Newsl. 5:28-34, 1986).
In a national collaborative study conducted in 1984, 15.2% of
a large number of strains of H. influenzae produced I-
lactamase (6). The problem of ampicillin resistance is com-
plicated by recent descriptions of clinical isolates of H.
influenzae that are resistant to ampicillin by mechanisms
other than the production of a TEM-type P-lactamase (10,
11, 14). In addition, chloramphenicol resistance has now
been reported (2, 15), as has resistance to a variety of
alternative agents commonly used to treat Haemophilus
infections (Doern, Antimicrob. Newsl. 5:28-34). The intent
of this investigation was to define systematically the preva-
lence of antimicrobial resistance among clinical isolates of
H. influenzae in the United States. Rates of P-lactamase
production and the activities of 12 antimicrobial agents were
assessed. These agents included ampicillin, chloramphenicol,
cefamandole, cefaclor, cephalothin, cephalexin, tetracycline,
rifampin, erythromycin, sulfisoxazole, and the combinations
erythromycin-sulfisoxazole and trimethoprim-sulfamethox-
azole (TMP-SMX).
MATERIALS AND METHODS
Study centers. A total of 30 hospital-based microbiology
laboratories and 1 national, private, independent laboratory
participated in the study (Table 1).
Clinical isolates. A total of 2,811 clinical isolates of H.
influenzae were obtained as part of this investigation in 1986
* Corresponding author.
by the laboratories listed in Table 1. All isolates were
recovered from different patients and were randomly se-
lected for inclusion in the study. After being characterized in
study center laboratories, isolates were subcultured to choc-
olate agar slants (GIBCO Diagnostics, Madison, Wis.),
which were incubated overnight in a CO2 atmosphere and
then mailed, with selected patient demographic information,
to one of two coordinating study centers for further charac-
terization. The coordinating study centers were the Depart-
ment of Clinical Microbiology, University of Massachusetts
Medical Center, Worcester, and the Department of Pathol-
ogy, University of Texas Health Science Center, San Anto-
nio. Upon receipt in the coordinating study centers, growth
from slants was transferred into 10% sterile skim milk and
frozen at -70°C in 1-dram (ca. 3.7-ml) plastic freezer vials.
Isolate characterization. Frozen stock suspensions were
thawed, and aliquots were subcultured to chocolate agar
plates (GIBCO) which were incubated overnight at 35°C in 5
to 7% CO2. Individual isolated colonies were then subcul-
tured to a second chocolate agar plate which was incubated
under identical conditions. Growth from the second plate
was used for the following analyses. Organisms were iden-
tified as H. influenzae on the basis of the following charac-
teristics: typical colony and Gram stain morphology (8),
catalase production (7), hemin dependence on the basis of
the porphyrin test (8), and lack of hemolysis when grown on
tryptic soy agar plates containing 5% horse blood agar and
1% IsoVitaleX (BBL Microbiology Systems, Cockeysville,
Md.). Isolates identified as H. influenzae were further exam-
ined for type b capsular antigen by a slide agglutination
procedure (8) which uses H. influenzae type b antiserum
(Burroughs Wellcome, Co., Research Triangle Park, N.C.).
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TABLE 1. Sources of H. influenzae isolates and prevalence of
,B-lactamase production
Study No. of strains (% P-lactamase positive)
center' Type b Non-type b
Northeast
BVA
UCHC
CHB
NYUMC
LIJMC
TJH
SCHC
20 (10.0)
59 (24.5)
24 (25.0)
17 (94.1)
53 (32.1)
13 (7.7)
31 (22.6)
71 (8.5)
41 (22.0)
62 (24.2)
75 (0.0)
50 (24.0)
74 (13.5)
62 (22.6)
Southeast
MCV 39 (33.3) 53 (18.9)
JCVA 2 (0.0) 79 (10.1)
VUMC 47 (23.4) 48 (29.2)
MUSC 27 (25.9) 58 (8.6)
GMH 14 (50.0) 78 (9.0)
BCH 42 (23.8) 57 (26.3)
Midwest
OSUH 27 (14.8) 67 (10.5)
CCH 23 (26.1) 63 (19.1)
NUMH 12 (16.7) 49 (22.5)
EH 23 (60.9) 64 (15.6)
MCW 3 (0.0) 83 (14.5)
CHW 38 (34.2) 51 (15.7)
SPRMC 10 (40.0) 55 (9.1)
SLCH 39 (43.6) 33 (18.2)
Southwest
HH 19 (47.4) 76 (8.6)
MCH 26 (26.9) 45 (28.9)
LMC 5 (40.0) 58 (17.2)
GSMC 34 (38.2) 60 (16.7)
West
UCLA 10 (20.0) 73 (17.8)
LLUMC 10 (50.0) 82 (20.7)
IDMG 4 (50.0) 34 (17.7)
KPRL 31 (32.3) 44 (20.5)
COH 42 (40.5) 55 (29.1)
Nationwide
MML 13 (7.7) 254 (10.6)
Totals 757 (31.7) 2,054 (15.6)
a BVA, Veterans Administration Hospital, Boston, Mass; UCHC, Univer-
sity of Connecticut Health Center, Farmington; CHB, Children's Hospital of
Buffalo, Buffalo, N.Y.; NYUMC, New York University Medical Center, New
York; LUJMC, Long Island Jewish Hillside Medical Center, New Hyde Park,
N.Y.; TJH, Thomas Jefferson Hospital, Philadelphia, Pa.; SCHC, St. Christo-
pher's Hospital for Children, Philadelphia, Pa.; MCV, Medical College of
Virginia, Richmond; JCVA, Veterans Administration Medical Center, John-
son City, Tenn.; VUMC, Vanderbilt University Medical Center, Nashville,
Tenn.; MUSC, Medical University of South Carolina, Charleston; GMH,
Grady Memorial Hospital, Atlanta, Ga.; BCH, Children's Hospital, Birming-
ham, Ala.; OSUH, Ohio State University Hospitals, Columbus; CCH, Chil-
dren's Hospital Medical Center, Cincinnati, Ohio; NUMH, Northwestern
University Memorial Hospital, Chicago, Ill.; EH, Evanston Hospital, Evan-
ston, Ill.; MCW, Medical College of Wisconsin, Milwaukee; CHW, Children's
Hospital of Wisconsin, Milwaukee; SPRMC, St. Paul-Ramsey Medical Cen-
ter, St. Paul, Minn.; SLCH, St. Louis Children's Hospital, St. Louis, Mo.;
HH, Herman Hospital, Houston, Tex.; MCH, Medical Center Hospital, San
Antonio, Tex.; LMC, Lovelace Medical Center, Albuquerque, N.Mex.;
GSMC, Good Samaritan Medical Center, Phoenix, Ariz.; UCLA, University
of California at Los Angeles Hospital, Los Angeles; LLUMC, Loma Linda
University Medical Center, Loma Linda, Calif.; IDMG, Infectious Disease
Medical Group, Oakland, Calif.; KPRL, Kaiser Permanente Regional Labo-
ratory, Portland, Oreg.; COH, Children's Orthopedic Hospital, Seattle,
Wash.; MML, Metpath Microbiology Laboratory, Teterboro, N.J.
TABLE 2. Ages of patients from whom H. influenzae
was recovered
Total no. No. of strains
Age group (%) of (% 13-lactamase positive)
strains Type b Non-type b
Not indicated 227 (8.1) 53 (32.1) 174 (16.7)
0-1 mo 44 (1.6) 5 (20.0) 39 (12.8)
2 mo-2 yr 824 (29.3) 424 (34.0) 400 (24.5)
>2-5 yr 233 (8.3) 106 (30.2) 127 (19.7)
>5-10 yr 120 (4.3) 27 (40.7) 93 (15.1)
>10-20 yr 172 (6.1) 11 (36.4) 161 (14.9)
>20-50 yr 507 (18.0) 54 (27.8) 453 (13.0)
>50 yr 684 (24.3) 77 (20.8) 607 (11.0)
In addition, ,B-lactamase production was assessed with ni-
trocefin-impregnated paper disks (Cefinase disks; BBL) (12).
Selected isolates were tested for chloramphenicol acetyl-
transferase activity by the method of Azumen and co-
workers (1). H. influenzae strains with known reactivities
were used as test controls.
Antimicrobial susceptibility testing. MICs were determined
with commercially prepared dehydrated microdilution sus-
ceptibility test plates (Sensititre, Inc., Salem, N.H.). The 12
antimicrobial agents were examined against all study isolates
at the following ranges of concentrations: ampicillin, chlor-
amphenicol, cephalothin, cephalexin, cefaclor, cefaman-
dole, tetracycline, erythromycin, and sulfisoxazole, 0.008 to
256 pLg/ml; erythromycin-sulfisoxazole, 0.008/0.5 to 16/1,024
,ug/ml; TMP-SMX, 0.008/0.15 to 32/608 ,ug/ml; and rifampin,
0.008 to 128 ,g/ml.
Microdilution test plates were inoculated (100 ,lI per well)
with a suspension of test organism (1 x 105 to 5 x 105
CFU/ml) in Haemophilus Test Medium by using an auto-
mated inoculator (Sensititre). Haemophilus test medium
consisted of Mueller-Hinton broth (GIBCO or Difco Labo-
ratories, Detroit, Mich.), 15 ,ug of P-NAD (Sigma Chemical
Co., St. Louis, Mo.) per ml, 15 ,ug of bovine hematin (Sigma)
per ml, 5 mg of yeast extract (GIBCO or Scott Laboratories,
Inc., Fiskeville, R.I.) per ml, 0.2 IU of thymidine phos-
phorylase (Burroughs Wellcome) per ml, 25 mg of magne-
sium per liter, and 50 mg of calcium per liter, at pH 7.3 (J. H.
Jorgensen, J. S. Redding, L. A. Maher, and A. W. Howell,
Abstr. Annu. Meet. Am. Soc. Microbiol. 1987, C-219, p.
359). Microdilution test plates were incubated for 20 to 24 h
at 35°C in ambient air, and wells were examined macroscop-
TABLE 3. Specimen types from which H. influenzae
was recovered
Specimen Total no. No. of strainsSpeimn (%) of (% ,3-lactamase positive)
strains Type b Non-type b
Not indicated 28 (1.0) 3 (66.7) 25 (12.0)
Blood 322 (11.5) 254 (33.1) 68 (19.1)
CSF 266 (9.5) 259 (34.0) 7 (0.0)
Body fluid 28 (1.0) 10 (50.0) 18 (5.6)
Sputum 970 (34.5) 103 (15.5) 867 (12.7)
TTA 101 (3.6) 12 (50.0) 89 (14.6)
Middle ear fluid 81 (2.9) 8 (12.5) 73 (26.0)
URT 414 (14.7) 44 (45.5) 370 (16.2)
Eye 395 (14.1) 33 (24.2) 362 (18.0)
Other 206 (7.3) 31 (32.3) 175 (21.1)
a CSF, Cerebrospinal fluid; TTA, transtracheal aspirate; URT, upper
respiratory tract.
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TABLE 4. MICs of selected beta-lactam antimicrobial agents for 561 P-lactamase-positive strains and 2,250 P-lactamase-negative strains
of H. influenzae
Antimicrobial No. of strains (cumulative %) for which MIC (>g/ml) was as follows:
agent -Lactamase <0.015 0.03 0.06 0.125 0.25 0.5 1.0
Ampicillin Positive
Negative 1 (0.04) 11 (0.5) 67 (3.5) 752 (36.9) 1,238 (92.0) 110 (96.8)
Cephalexin Positive
Negative 1 (0.04) 1 (0.1) 3 (0.2) 9 (0.6)
Cephalothin Positive 2 (0.4) 6 (1.9) 26 (6.5)
Negative 4 (0.2) 18 (1.0) 46 (3.0) 203 (12.0)
Cefaclor Positive 3 (0.5) 25 (5.0)
Negative 2 (0.1) 2 (0.2) 2 (0.3) 1 (0.3) 23 (1.3) 89 (5.3)
Cefamandole Positive 5 (0.9) 42 (8.4) 194 (43.0)
Negative 1 (0.04) 1 (0.1) 14 (0.7) 48 (2.8) 481 (24.2) 1,167 (76.1)
ically for evidence of growth. An MIC was defined as the produced ,B-lactamase (Table 1). The overall prevalence of
lowest concentration of antimicrobial agent tested which t-lactamase production among the 2,811 study isolates was
inhibited growth. A strain of H. influenzae for which the thus 20.0%. In general, whether isolates were categorized by
MICs of the antimicrobial agents are known was used as a study center (Table 1), patient age (Table 2), or specimen
daily control. source (Table 3), type b strains were more likely to produce
P-lactamase than were non-type b strains.
RESULTS The in vitro activities of five beta-lactam antimicrobial
agents against the 2,811 study isolates are shown in Table 4.
A total of 2,811 clinical isolates of H. influenzae were For all of the 561 P-lactamase-producing strains, ampicillin
examined (Table 1). Among these, 757 (26.9%) were encap- MICs were .2.0 ,xg/ml. Indeed, for most of these strains
sulated type b strains, and 2,054 (72.1%) were non-type b (i.e., 452 or 80.6%), ampicillin MICs were .16 ,ug/ml. For
strains. The number of isolates contributed by each of the 30 2,179 of 2,250 isolates (96.8%) that lacked ,B-lactamase,
hospital-based study centers varied from a low of 38 (Infec- ampicillin MICs were '1.0 ,ug/ml. For 69 P-lactamase-
tious Disease Medical Group) to a high of 103 (Long Island negative strains (8 type b and 61 non-type b strains), ampi-
Jewish Hillside Medical Center), with a mean of 85 isolates cillin MICs were 2.0 or 4.0 ,ug/ml. In addition, two non-type
per center. In addition, 267 isolates were contributed by b strains for which MICs were 16 and 32 p.g/ml demonstrated
Metpath Microbiology Laboratory, a nationwide, private, high-level ampicillin resistance despite the absence of ,B-
independent laboratory. lactamase activity.
The largest number of type b strains were obtained from Cephalexin, cephalothin, cefaclor, and cefamandole had
patients between the ages of 2 months and 2 years (Table 2). variable activities against the study isolates (Table 4). In
In contrast, non-type b strains were obtained most fre- general, cefamandole was the most active agent, followed by
quently from patients greater than 50 years of age. Type b cefaclor, cephalothin, and cephalexin. With these four anti-
strains were recovered most frequently from blood and microbial agents, in vitro activity was not noticeably influ-
cerebrospinal fluid, while sputum, upper respiratory tract, enced by ,-lactamase production. On the basis of the MIC
and eye cultures were the most common sources of non-type interpretative standards of the National Committee for Clin-
b strains (Table 3). ical Laboratory Standards (NCCLS), i.e., MICs of -8.0
The overall rate of ,-lactamase production among type b ,ug/ml indicate susceptibility (13), the overall percentages of
strains was 31.7%. In contrast, 15.6% of non-type b strains study isolates susceptible to cefamandole, cefaclor, cepha-
TABLE 5. MICs of seven antimicrobial agents for 2,811 clinical isolates of H. influenzae
Antimicrobial No. of strains (cumulative %) for which MIC (jjg/ml) was as follows:
agent
-0.008 0.015 0.03 0.06 0.125 0.25 0.5
Chloramphenicol 2 (0.1) 11 (0.5) 80 (3.3) 1,828 (68.3)
Tetracycline 3 (0.1) 28 (1.1) 709 (26.3)
Erythromycin 2 (0.1) 3 (0.2) 18 (0.8) 6 (1.0)
Erythro-sulfaa 2 (0.1) 2 (0.2) 7 (0.4) 25 (1.3) 105 (5.0) 339 (17.1) 569 (37.3)
Sulfisoxazole 2 (0.1) 1 (0.1) 3 (0.2)
TMP-SMXb 58 (2.1) 134 (6.8) 694 (31.5) 1,386 (80.8) 463 (97.3) 43 (98.8) 8 (99.1)
Rifampin 2 (0.1) 4 (0.2) 1 (0.3) 11 (0.6) 244 (9.3) 1,523 (63.5) 1,005 (99.3)
a Erythro-sulfa, Erythromycin-sulfisoxazole. This combination was tested at a constant ratio of 1 part of erythromycin to 64 parts of sulfisoxazole; the
concentration indicated is the concentration of erythromycin.
b This combination was tested at a constant ratio of 1 part of trimethoprim to 19 parts of sulfamethoxazole; the concentration indicated is the concentration
of trimethoprim.
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TABLE 4-Continued
No. of strains (cumulative %) for which MIC (Lg/ml) was as follows:
2.0 4.0 8.0 16 32 64 128 256 >256
17 (3.0) 33 (8.9) 59 (19.4) 93 (36.0) 142 (61.3) 106 (80.2) 66 (92.0) 26 (96.6) 19 (100)
65 (99.7) 4 (99.9) 1 (99.9) 1 (100)
8 (1.4) 25 (5.9) 280 (55.8) 130 (79.0) 64 (90.4) 51 (99.5) 3 (100)
40 (2.4) 71 (5.6) 778 (40.1) 708 (71.6) 328 (86.2) 239 (96.8) 35 (98.4) 19 (99.2) 18 (100)
104 (25.0) 117 (45.9) 202 (81.9) 77 (95.6) 24 (99.5) 3 (100)
568 (37.3) 480 (58.6) 677 (88.7) 220 (98.5) 32 (99.9) 2 (100)
115 (25.5) 243 (68.8) 128 (91.6) 29 (96.8) 6 (97.9) 7 (99.1) 5 (100)
571 (30.6) 1,094 (79.3) 358 (95.2) 74 (98.5) 25 (99.6) 7 (99.9) 1 (99.9) 1 (100)
238 (85.4) 54 (95.0) 22 (98.9) 5 (99.8) 1 (100)
419 (95.7) 57 (97.2) 32 (98.7) 22 (99.6) 6 (99.9) 2 (100)
lothin, and cephalexin were 98.7, 94.5, 87.3, and 43.3%, type b and 44 non-type b strains), 23 (35.9%; 5 type b and 18
respectively. non-type b strains) produced P-lactamase.
The MICs of chloramphenicol, tetracycline, erythromy- Erythromycin was relatively inactive (Table 5). Only 29
cin, erythromycin-sulfisoxazole (1/64), sulfisoxazole, TMP- strains (1.0%) were susceptible on the basis of the criterion
SMX (1/19), and rifampin are shown in Table 5. No differ- of the NCCLS, i.e., MICs of c0.5 ,ug/ml (13). Similarly,
ences were observed when the results obtained with these sulfisoxazole was, in general, inhibitory only at high concen-
seven agents against P-lactamase-producing strains were trations. The combination of erythromycin and sulfisoxazole
compared with those obtained against strains that lacked was considerably more active than erythromycin alone but
P-lactamase. Chloramphenicol MICs for 2,797 isolates essentially equivalent to sulfisoxazole alone. Unfortunately,
(99.5% of the total) were <4.0 ,ug/ml. For the remaining 14 insufficient information exists upon which to base calcula-
strains (0.5% of the total; 2 type b and 12 non-type b strains), tions of a percent susceptible value for the combination
chloramphenicol MICs were .8.0 ,g/ml; all of these strains erythromycin-sulfisoxazole.
produced chloramphenicol acetyltransferase. Eleven strains Among 2,811 study isolates, 25 (0.9%; 5 type b and 20
(2 type b, and 9 non-type b stains) were P-lactamase posi- non-type b isolates) were not susceptible to TMP-SMX on
tive. For all 14 strains, tetracycline MICs were -8.0 p.g/ml. the basis of the NCCLS definition of susceptibility to TMP-
From the 2,797 isolates for which chloramphenicol MICs SMX, i.e., MICs of c0.5/9.5 ,ug/ml (Table 5) (13). Of these
were c4.0 ,ug/ml, 50 strains were selected for the assessment 25 strains, 17 (2 type b and 15 non-type b strains) were also
of chloramphenicol acetyltransferase production. These in- P-lactamase positive. For 3 isolates (all 3-lactamase produc-
cluded 3 strains for which the MIC was 4.0 jig/ml, 1 strain for ing and non-type b) among the 25 strains that were not
which the MIC was 2.0 ,ug/ml, 20 strains for which the MIC susceptible to TMP-SMX, chloramphenicol and tetracycline
was 1.0 ,ug/ml, 20 strains for which the MIC was 0.5 ,uglml, MICs were .8.0 ,g/ml. For these three strains, the actual
and 6 strains for which the MIC was 0.25 ,ug/ml. None TMP-SMX MICs were 2.0/38, 4.0/76, and 4.0/76 jig/ml. In
produced chloramphenicol acetyltransferase. For 50 of 2,797 addition, for one 3-lactamase-negative, non-type b strain of
isolates (1.8%) for which chloramphenicol MICs were s4.0 H. influenzae which was not susceptible to TMP-SMX, the
,g/ml, tetracycline MICs were .8.0 p,g/ml. tetracycline MIC was 16 ,ug/ml. The strain was susceptible to
A total of 2,747 study isolates (97.7% of the total) were chloramphenicol (MIC, 1.0 ,ug/ml).The TMP-SMX MIC for
susceptible to tetracycline on the basis of the NCCLS this strain was 16/304 ,ug/ml.
guideline, i.e., MICs of c4.0 ,ug/ml (Table 5) (13). Of 64 Finally, for9 of 2,811 study isolates (0.7%), rifampin MICs
strains for which tetracycline MICs were .8.0 ,ug/ml (20 were .4 ,ug/ml; thus, these 9 strains were not susceptible to
TABLE 5-Continued
No. of strains (cumulative %) for which MIC (pLg/ml) was as follows:
1.0 2.0 4.0 8.0 16 32 64 128 >128
872 (99.4) 1 (99.4) 3 (99-5) 8 (99.8) 6 (100)
1,869 (92.8) 136 (97.7) 2 (97.7) 8 (98.0) 47 (99.7) 9 (100)
55 (3.0) 179 (9.4) 1,113 (49.0) 1,258 (93.7) 176 (99.9) 1 (100)
723 (63.0) 786 (91.0) 252 (99.9) 1 (100)
4 (0.4) 23 (1.2) 37 (2.5) 158 (8.1) 416 (22.9) 567 (43.1) 670 (66.9) 420 (81.9) 510 (100)
1 (99.2) 4 (99.3) 12 (99.7) 4 (99.9) 4 (100)
11 (99.6) 1 (99.7) 1 (99.7) 2 (99.8) 1 (99.8) 1 (99.9) 2 (99.9) 2 (100)
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this agent on the basis of the NCCLS criterion (Table 5) (13).
All nine strains were non-type b, ,-lactamase negative, and
susceptible to ampicillin, chloramphenicol, tetracycline, and
TMP-SMX.
DISCUSSION
The results of this investigation suggest that the preva-
lence of 3-lactamase-mediated ampicillin resistance among
clinical isolates of H. influenzae is increasing in the United
States. In a nationwide surveillance study conducted in
1984, 21.0% of 1,156 type b strains and 12.1% of 2,200
non-type b strains produced 1-lactamase (6). The present
investigation with isolates obtained in 1986 showed that
31.7% of 757 type b strains and 15.6% of 2,054 non-type b
strains were P-lactamase positive. Two observations made
in the 1984 study were corroborated by the results of the
present investigation. First, the overall rates of j-lactamase
production were highest among H. influenzae isolates from
patients in certain age groups (i.e., <5 years of age) and
among isolates from specimens representative of systemic
Haemophilus infections (i.e., blood and cerebrospinal fluid).
This observation was largely a result of the greater numbers
of type b strains recovered from younger patients and from
systemic sites. Second, it was not possible to predict with
certainty the prevalence of P-lactamase-positive H. influ-
enzae for a given geographic area, because of the absence of
any observed geographic clustering of ,-lactamase-pro-
ducing strains. As a result, predictions of rates of P-lac-
tamase production must be based on the experiences of
individual medical centers.
It is very likely that the P-lactamase-positive strains of H.
influenzae recovered in the present investigation produced a
TEM-1-type P-lactamase. This assumption is based on two
observations. First, the vast majority of 3-lactamase-pro-
ducing strains of H. influenzae possess this enzyme (Doem,
Antimicrob. Newsl. 5:28-34). Second, the nitrocefin disk
test used to detect P-lactamase activity in the present study
does not yield positive results with strains that possess the
ROB-type P-lactamase (10), the only other 1-lactamase
described for H. influenzae.
If this is true, it appears that high-level ampicillin resis-
tance among H. influenzae strains that lack the TEM-type
1-lactamase is extremely uncommon in the United States.
For only 2 isolates (both non-type b) from among 2,250
P-lactamase-negative strains characterized in this study
were ampicillin MICs .16 ,ug/ml. In addition, for four
3-lactamase-negative isolates (all non-type b), ampicillin
MICs were 4.0 pug/ml, and thus the isolates would be
considered resistant on the basis of the criteria of the
NCCLS (13). Of interest, however, is the observation that
for 65 isolates which lacked ,-lactamase, the ampicillin MIC
was 2.0 ,ug/ml. These isolates might be considered moder-
ately susceptible or even resistant to ampicillin despite the
recommendations of the NCCLS (13), which suggests that
H. influenzae strains for which ampicillin MICs are <2.0
,ug/ml be considered susceptible (4). We base this assertion
on the observation that for 17 ,-lactamase-positive strains in
the present study, the ampicillin MIC was 2.0 ,ug/ml. If H.
influenzae strains for which ampicillin MICs are .2.0 ,ug/ml
were considered resistant, then the overall rate of ampicillin
resistance among ,B-lactamase-negative isolates would be
3.2%.
Four cephalosporin antimicrobial agents were examined.
Their activities against H. influenzae were in the following
order: cefamandole > cefaclor . cephalothin > cephalexin.
Only 36 strains (1.3% of the total) were not susceptible to
cefamandole. In contrast, 155 (5.5% of the total) and 358
(12.7% of the total) strains were not susceptible to cefaclor
and cephalothin, respectively. Cephalexin had limited activ-
ity against H. influenzae. Isolates were considered suscep-
tible to these four cephalosporins if MICs were s8.0 p,g/ml
(13). Cephalosporin activity did not seem to be influenced by
P-lactamase activity, that is, the MICs of a given agent were
similar for P-lactamase-positive and -negative strains.
Chloramphenicol resistance appears to be relatively un-
common in the United States. For 14 strains (0.5% of the
total), chloramphenicol MICs were .8.0 p,g/ml, and thus
these strains were considered resistant (5). All of these
strains produced chloramphenicol acetyltransferase, and all
were resistant to tetracycline. Two were type b strains; both
produced ,B-lactamase. Of the 12 non-type b, chloramphen-
icol-resistant strains, 9 produced 1-lactamase.
Tetracycline was also highly active against most study
isolates. Among all strains tested, 97.7% were determined to
be susceptible to tetracycline based on the NCCLS-recom-
mended MIC breakpoint of s4.0 ,ug/ml (13). In contrast,
both erythromycin and sulfisoxazole had limited activities
against the H. influenzae strains examined in this investiga-
tion. Interestingly, erythromycin-sulfisoxazole, a combina-
tion frequently used to treat localized non-life-threatening
Haemophilus infections in children, was considerably more
active than erythromycin alone but equivalent in activity to
sulfisoxazole alone. Clinical interpretation of MICs obtained
with this combination, however, is difficult. For this inves-
tigation, a ratio of 1 part of erythromycin to 64 parts of
sulfisoxazole was used to determine MICs (P. N. Whitley
and S. I. Pelton, Program Abstr. 21st Intersci. Conf. Anti-
microb. Agents Chemother., abstr. no. 11, 1981). For these
in vitro observations of inhibitory activity to have clinical
relevance, a ratio of erythromycin to sulfisoxazole of ap-
proximately 1:64 would have to be achieved in vivo when
this combination is used to treat Haemophilus infections. At
least with respect to otitis media, the ratio of erythromycin
to sulfisoxazole obtained in middle ear fluid appears to be
much lower (9).
While TMP-SMX was highly active against most study
isolates, for 25 strains (0.9% of the total) MICs were -1.0/19jig/ml, and thus these strains were not considered suscepti-
ble by NCCLS criteria (13). Notable were 3 non-type b
strains among these 25 that also demonstrated resistance to
chloramphenicol and tetracycline, as well as 1-lactamase-
mediated ampicillin resistance. These strains seem similar to
the multiply resistant strains of H. influenzae recently re-
ported in Barcelona, Spain (3). Finally, the results of the
present investigation clearly documented the existence of at
least small numbers of clinical isolates of H. influenzae with
high-level resistance to rifampin.
In conclusion, the results of this extensive national sur-
veillance study of antimicrobial resistance among clinical
isolates of H. influenzae revealed the following. (i) The
prevalence of ,B-lactamase-mediated ampicillin resistance
continues to increase with both type b and non-type b strains.
The rate of P-lactamase-mediated ampicillin resistance among
type b strains (i.e., 31.7%) indicates that the use of ampicillin
alone for the empiric therapy of systemic Haemophilus infec-
tions is inappropriate. (ii) H. influenzae strains that are
resistant to ampicillin by mechanisms other than the produc-
tion of TEM-type P-lactamase are extremely uncommon. (iii)
Chloramphenicol resistance is also unusual; however, when it
occurs, it is invariably the result of chloramphenicol acetyl-
transferase production and is associated with P-lactamase
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production and tetracycline resistance. (iv) Resistance to
TMP-SMX and rifampin, two antimicrobial agents previously
considered nearly uniformly active against H. influenzae, was
clearly documented. Fortunately, resistance to these agents
remains uncommon; however, in the case of TMP-SMX it
may co-occur with P-lactamase-mediated ampicillin resis-
tance and resistance to chloramphenicol and tetracycline. (v)
Cephalexin and erythromycin have no value in the treatment
of infections caused by H. influenzae.
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